Aleksander A. Mathé, MD, PhD Professor of Psychiatry, Clinical Neuroscience, Karolinska Institutet Phone +4670 4840743; +4670 6825669 email aleksander.mathe@ki.se

- *Research focus -ongoing projects:
- 1. Intranasal neuropeptide Y: Development of principally novel treatments for major depressive disorder and PTSD
- 2. Treatment resistant major depression and insulin: preclinical and clinical studies
- 3. Genetic and epigenetic studies of depression, PTSD and anxiety in rodent models. Identification of biological markers and development of novel treatments, e.g., Lacetyl carnitine (LAC), neuropeptide S, neuropeptide Y
- *MD:1959
- *1960–1969: Interne, Resident and Teaching Fellow in Internal Medicine, Psychiatry: Bellevue Hospital-NYU; KI; MGH-Harvard Medical School;
- *1969-1984: NHLBI Fellowship: Visiting Scientist, Physiology; KI Assistant Professor and Associate Professor, Psychiatry & Pharmacology, and Director, Laboratory Biogenic Amines and Allergy, BUSM; Mount Sinai School of Medicine
- *1984–1996: Associate Professor, Psychiatry, KI
- *1996-current: Professor, Clinical Neuroscience KI; Head, Neuropeptide Lab
- *PhD, 1976: Department of Physiology (Ulf von Euler), Karolinska Institutet (KI) Studies on actions of prostaglandins in the lung Acta Physiol Scand 441:1976
- *Active Medical Licenses: USA, Sweden
- *Certifications: Diplomate American Board of Psychiatry and Neurology; Swedish Board Certified in Psychiatry
- *Professional societies:

American College of Allergy, Asthma and Immunology (ACAAI)

American College of Neuropsychopharmacology (ACNP), Fellow

American Psychiatric Association, Life Fellow

American Society for Pharmacology and Experimental Therapeutics (FASEB)

International Neuropeptide Society, Fellow and Life Member

- *Committees:
- i. ACNP Membership Committee
- ii. Program Committee Annual Meeting, Society for Biological Psychiatry
- iii. Member, Committee for drug usage, Stockholm County Council
- * Editorial Boards: Acta Neuropsych; Int J Neuropsychopharm; Arch Clin Depression & Anxiety;

J Psychiatric Res; Current Psych Rev; J Psychol Psychother Research; The Open

Neuropsychopharm J; The Open Neuroendocrinol J; World J Pharmacol, World J Psychiatry

*Reviewer Granting Agencies: Agence National de la Recherche (France); Deutsche

Forschungsgemeinschaft; European Commission (other: Austrian Res. Council; Israel Science Foundation; Italian Res. Council; NHLBI; NIMH; Polish-Swiss Sci. Foundation; Welcome Trust)